Antibody Screening Elisa

Description: Human PVRIG (poliovirus receptor related immunoglobulin domain-containing protein), also known as CD112 receptor (CD112R), is an approximately 34 kDa single transmembrane protein in the poliovirus receptor-like protein (PVR) family. The CD112R gene encodes a putative single transmembrane protein, which is composed of a single extracellular IgV domain, one transmembrane domain, and a long intracellular domain. Notably, the intracellular domain of phatases. The extracellular domain sequence of human and mouse CD112R have 65.3% similarity. CD112R may act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals.

Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Monkey True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: Colon carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases/100 cores

Description: BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

Description: BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

Description: Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.

Description: Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.

Description: BCMA (B cell maturation antigen), a member of the tumor necrosis factor receptor family. BCMA is mainly expressed on the surface of advanced B cells, short-lived proliferating plasmablasts and long-lived plasma cells, but not in naive B cells, CD34-positive hematopoietic stem cells and other normal tissue cells. With its specific expression ability, BCMA has become a good diagnostic marker and therapeutic target for multiple myeloma (MM).The main ligands of BCMA are BAFF and APRIL. When BCMA was combined with APRIL, the expression level of immune checkpoint was up-regulated to create an immunosuppressive bone marrow microenvironment. APRIL, as an important ligand of BCMA, is a member of the TNF(Tumor necrosis factor) receptor family (TNFSF-13A), which has 30% sequence homology with BAFF, another ligand of BCMA. But it has a higher affinity to interact with BCMA. It consists of 250 amino acids, of which 28 amino acids encode intracellular regions and 201 amino acids encode type II transmembrane proteins and their extracellular regions. The binding of APRIL to BCMA also induces both classical and non-classical NF-κB pathways, further promoting angiogenesis and metastasis, as well as tumor cell growth and proliferation.

Description: BCMA (B cell maturation antigen), a member of the tumor necrosis factor receptor family. BCMA is mainly expressed on the surface of advanced B cells, short-lived proliferating plasmablasts and long-lived plasma cells, but not in naive B cells, CD34-positive hematopoietic stem cells and other normal tissue cells. With its specific expression ability, BCMA has become a good diagnostic marker and therapeutic target for multiple myeloma (MM).The main ligands of BCMA are BAFF and APRIL. When BCMA was combined with APRIL, the expression level of immune checkpoint was up-regulated to create an immunosuppressive bone marrow microenvironment. APRIL, as an important ligand of BCMA, is a member of the TNF(Tumor necrosis factor) receptor family (TNFSF-13A), which has 30% sequence homology with BAFF, another ligand of BCMA. But it has a higher affinity to interact with BCMA. It consists of 250 amino acids, of which 28 amino acids encode intracellular regions and 201 amino acids encode type II transmembrane proteins and their extracellular regions. The binding of APRIL to BCMA also induces both classical and non-classical NF-κB pathways, further promoting angiogenesis and metastasis, as well as tumor cell growth and proliferation.

Description: CD30 belongs to the tumor necrosis factor receptor (TNFR) superfamily, and the physiological functions of CD30 are in addition to the transmission of synergistic stimulation signals. CD30 ligand (CD30L) belongs to the tumor necrosis factor (TNF) superfamily, and CD30L is present in activated T cells, quiescent B cells, granulocytes, thymic medullary cells, and various leukemia cells. After crosslinking CD30 and CD30L, diverse physiological function signaling is led by TNFR correlation factors (TRAF), including TRAF1, 2, 3, 5. CD30 was originally found in Hodgkin's lymphoma and Reed Sternberg (RS) cells, and is now known to be expressed on the surface of some normal lymphocytes, virally infected lymphocytes, lymphocytes of lymphogenetic origin, and activated T cell subsets that produce Th2 cytokines.

Description: CD30 belongs to the tumor necrosis factor receptor (TNFR) superfamily, and the physiological functions of CD30 are in addition to the transmission of synergistic stimulation signals. CD30 ligand (CD30L) belongs to the tumor necrosis factor (TNF) superfamily, and CD30L is present in activated T cells, quiescent B cells, granulocytes, thymic medullary cells, and various leukemia cells. After crosslinking CD30 and CD30L, diverse physiological function signaling is led by TNFR correlation factors (TRAF), including TRAF1, 2, 3, 5. CD30 was originally found in Hodgkin's lymphoma and Reed Sternberg (RS) cells, and is now known to be expressed on the surface of some normal lymphocytes, virally infected lymphocytes, lymphocytes of lymphogenetic origin, and activated T cell subsets that produce Th2 cytokines.

Description: Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

Description: Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

Description: Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

Description: Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

Description: Esophagus cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases/100 cores

Description: CD155 and ITIM domains (TIGIT) is a novel type of immune checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression and promotes the proliferative and migratory abilities of tumor cells via various pathways. TIGIT, an inhibitory receptor, is mainly expressed on natural killer (NK), CD8+ T, CD4+ T and T regulatory (Treg) cells. CD155 transmits immune signals via interacting with the inhibitory checkpoint receptor TIGIT, thereby inhibiting the function of T and NK cells.CD155 is highly expressed on the surface of DC cells. When TIGIT on T cells binds to CD155 on DC cells, CD155 will send signals to DC cells to up-regulate the secretion of IL-10 and down-regulate the secretion of IL-12, thereby weakening the immune response mediated by DC cells. DC cells are important antigen-presenting cells in the body, and reduced DC cell activity in turn reduces T cell activity.

Description: CD155 and ITIM domains (TIGIT) is a novel type of immune checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression and promotes the proliferative and migratory abilities of tumor cells via various pathways. TIGIT, an inhibitory receptor, is mainly expressed on natural killer (NK), CD8+ T, CD4+ T and T regulatory (Treg) cells. CD155 transmits immune signals via interacting with the inhibitory checkpoint receptor TIGIT, thereby inhibiting the function of T and NK cells.CD155 is highly expressed on the surface of DC cells. When TIGIT on T cells binds to CD155 on DC cells, CD155 will send signals to DC cells to up-regulate the secretion of IL-10 and down-regulate the secretion of IL-12, thereby weakening the immune response mediated by DC cells. DC cells are important antigen-presenting cells in the body, and reduced DC cell activity in turn reduces T cell activity.